← Leaderboards
Daniel Eidelberg Spratt
Case Western Reserve University
$5,099,108
Attributed
$10,198,215
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2019–25$2.5M$1.9M$1.3M$625K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,198,215 · 4
By mechanism
UG1$5,480,738 · 1
R01$3,062,870 · 1
U01$1,267,741 · 1
R21$386,866 · 1
Top collaborators
- Todd M. Morgan7 shared
- Aaron Thomas Gerds4 shared
- Yilun Sun3 shared
- Matthew Schipper1 shared
Most similar at Case Western Reserve University
Same institution · by research overlap
- Aaron Thomas Gerds$8,805,804
- Sanford D Markowitz$49,710,196
- Jonathan S. Stamler$32,849,627
- Laura A Siminoff$15,542,153
- J Sunil Rao$4,814,871
Others in their field
Other Emerging Leaders on “Prospective”
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$56,084,949
- Michael Dignam · National Institute Of Allergy And Infectious Diseases$31,845,607
- Stephen F Kry · University Of Tx Md Anderson Can Ctr$28,689,457
- Ellen Gould Chadwick · Harvard University D/B/A Harvard School Of Public Health$25,473,113
- Olwen Hahn · Brigham And Women'S Hospital$23,582,395
- Julie Ake · National Institute Of Allergy And Infectious Diseases$22,000,000
Research focus
ProspectiveQuality Of LifeMalignant NeoplasmsDiagnosisCancer PatientPersonalized MedicineMalignant Neoplasm Of ProstateRandomized TrialTissuesNewly DiagnosedProstatectomyPatient CareFutureRadical ProstatectomyRandomizedIncidenceBiopsyCancer CareFailureMelanomaGenomicsCancer EtiologyProstate Cancer RiskPatient Risk
Grant awards (15)
Case Comprehensive Cancer Center NCTN Lead Academic Participating Site$1,412,352
UG1 · FY2025 · CA
Quantifying and Personalizing the Clinical Benefit of Metastasis-Directed Therapy in Men with De Novo Oligometastatic Prostate Cancer$309,210
U01 · FY2025 · CA · contact PI
Case Comprehensive Cancer Center NCTN Lead Academic Participating Site$1,279,477
UG1 · FY2024 · CA
Quantifying and Personalizing the Clinical Benefit of Metastasis-Directed Therapy in Men with De Novo Oligometastatic Prostate Cancer$445,266
U01 · FY2024 · CA · contact PI
Determining the clinical impact of gene expression testing in localized prostate cancer$164,834
R01 · FY2024 · CA
Case Comprehensive Cancer Center NCTN Lead Academic Participating Site$1,363,981
UG1 · FY2023 · CA
Determining the clinical impact of gene expression testing in localized prostate cancer$473,428
R01 · FY2023 · CA
Individualized estimates of treatment benefit from hormone therapy for men with prostate cancer$386,866
R21 · FY2023 · CA
Case Comprehensive Cancer Center NCTN Lead Academic Participating Site$1,424,928
UG1 · FY2022 · CA
Determining the clinical impact of gene expression testing in localized prostate cancer$646,294
R01 · FY2022 · CA
Determining the clinical impact of gene expression testing in localized prostate cancer$694,220
R01 · FY2021 · CA
Quantifying and Personalizing the Clinical Benefit of Metastasis-Directed Therapy in Men with De Novo Oligometastatic Prostate Cancer$513,265
U01 · FY2021 · CA · contact PI
Determining the clinical impact of gene expression testing in localized prostate cancer$403,307
R01 · FY2020 · CA
Determining the clinical impact of gene expression testing in localized prostate cancer$62,870
R01 · FY2020 · CA
Determining the clinical impact of gene expression testing in localized prostate cancer$617,917
R01 · FY2019 · CA